| Oct 31 |
Genprex to Participate in 2024 BIO Europe Conference
|
| Oct 28 |
Looking Into Genprex's Recent Short Interest
|
| Oct 28 |
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma
|
| Oct 24 |
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive
|
| Oct 23 |
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
|
| Oct 16 |
Genprex advances to highest dose in Phase I Acclaim-3 trial of Reqorsa
|
| Oct 15 |
Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
|
| Sep 23 |
Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes
|
| Sep 19 |
Genprex Announces Formation of Mesothelioma Clinical Advisory Board
|
| Sep 9 |
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
|
